Quanterix Reports Q4 Revenue Beat, Increased FY25 Loss, Targets 2026 Cash Flow Breakeven

summarizeSummary

Quanterix announced Q4 2025 financial results, exceeding revenue expectations, and provided 2026 guidance targeting cash flow breakeven in the second half, alongside significant progress in Alzheimer's diagnostics.

check_boxKey Events

• Q4 2025 Revenue Beat

  Reported $43.9 million in Q4 revenue, a 25% increase year-over-year, exceeding expectations.

• Increased Full Year 2025 Net Loss

  Full year 2025 net loss significantly widened to $107.15 million, or $(2.51) per share, compared to $38.53 million in 2024.

• 2026 Cash Flow Breakeven Target

  Company expects to achieve cash flow breakeven in the second half of 2026 and exit the year with approximately $100 million in cash.

• Alzheimer's Diagnostics Progress

  Submitted a 510(k) premarket notification to the FDA for its multi-analyte Alzheimer's blood test and secured an $897 CMS reimbursement rate for its LucentAD Complete test.

auto_awesomeAnalysis

Quanterix reported a significant net loss for the full year 2025, consistent with the concurrent 10-K filing, but highlighted a strong fourth quarter revenue beat and substantial progress on cost synergies. The company's guidance for 2026, particularly the expectation to achieve cash flow breakeven in the second half and exit the year with approximately $100 million in cash, provides a critical outlook for investors. Strategic advancements in Alzheimer's diagnostics, including an FDA 510(k) submission and CMS reimbursement rate approval, further support the company's long-term growth strategy despite the challenging 2025 financial performance.